Post-covid: efficacy and safety of thiotriazoline

Саливончик Дмитрий Павлович

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali · 2022-yil

Annotatsiya

The use of Thiotriazoline at the outpatient stage in patients with past COVID-19 infection significantly reduces cell damage with a decrease in LDH levels in the main group from 362.5±192.9 to 221.2±98.8 U/l against the dynamics from 385.9 ±210.1 to 269.0±142.9 U/l in the control group, p=0.02, reduce ALT in the main group for a month of therapy from 69.7±35.6 U/l to 30.8± 15.5 U/l compared with the control group (from 63.7±52.7 U/l to 57.4±44.7 U/l, p=0.002). The clinical efficacy of Thiotriazoline in patients who predominantly had pneumonia against the background of COVID-19 infection was manifested in an improvement in the integral indicators of their quality of life over a 30-day follow-up period. Significant changes were registered in achieving a higher level of health both in the analysis of the integral indicator of physical health (IPH) - 58.1±17.7 points versus 50.2±24.9 points in the control group, and in the analysis of the integral indicator of mental health (IMH) - 70.9±16.4 points in the main group versus 51.4±21.7 points in the control group, respectively, p=0.003, in the absence of complications or side effects of the drug.

Maqola ma’lumotlari
MualliflarСаливончик Дмитрий Павлович
JurnalJournal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali
NashriyotСамарқанд давлат тиббиёт университети
Nashr sanasi2022-07-29
TilIngliz
Ilmiy sohaTibbiyot
Indeksga qo‘shilgan2026-08-26

Maqolaning asl sahifasi

Kalit so‘zlar

постковид, Тиотриазолин, эффективность, безопасность, качество жизни, post-covid, Thiotriazolin, efficacy, safety, quality of life, post-covid, Tiotriazolin, samaradorlik, xavfsizlik, hayot sifati

Ilmiy soha

Tibbiyot

Iqtibos keltirish

APAСаливончик Дмитрий Павлович (2022). POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE. Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali. https://www.tadqiqot.uz/index.php/cardio/article/view/5239
GOST (OAK)Саливончик Дмитрий Павлович POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE // Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali. – 2022.
MLAСаливончик Дмитрий Павлович. “POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE.” Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali, 2022. https://www.tadqiqot.uz/index.php/cardio/article/view/5239
ChicagoСаливончик Дмитрий Павлович. “POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE.” Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali (2022). https://www.tadqiqot.uz/index.php/cardio/article/view/5239
HarvardСаливончик Дмитрий Павлович (2022) ‘POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE’, Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali. https://www.tadqiqot.uz/index.php/cardio/article/view/5239
BibTeX
@article{article2022,
  title = {POST-COVID: EFFICACY AND SAFETY OF THIOTRIAZOLINE},
  author = {Саливончик Дмитрий Павлович},
  journal = {Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali},
  year = {2022},
  url = {https://www.tadqiqot.uz/index.php/cardio/article/view/5239}
}

Boshqa maqola uchun iqtibos tayyorlash

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali jurnalidan boshqa maqolalar

Journal of cardiorespiratory research/Kardiorespirator tadqiqotlar jurnali — barcha maqolalar · 2022-yil arxivi

Tibbiyot sohasidagi boshqa maqolalar

Tibbiyot sohasidagi OAK jurnallari